Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 150 No. 2930 (2020)

Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis

DOI
https://doi.org/10.4414/smw.2020.20316
Cite this as:
Swiss Med Wkly. 2020;150:w20316
Published
15.07.2020

Summary

AIMS OF THE STUDY

To describe admission characteristics, risk factors and outcomes of patients with coronavirus disease 2019 (COVID-19) hospitalised in a tertiary care hospital in Switzerland during the early phase of the pandemic.

METHODS

This retrospective cohort study included adult patients with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) testing and hospitalised at the cantonal hospital Aarau (Switzerland) between 26 February 2020 and 30 April 2020. Our primary endpoint was severe COVID-19 progression defined as a composite of transfer to the intensive care unit (ICU) and in-hospital mortality.

RESULTS

A total of 99 patients (median age 67 years [interquartile range 56–76], 37% females) were included and 35% developed severe COVID-19 progression (24% needed ICU treatment, 19% died). Patients had a high burden of comorbidities with a median Charlson comorbidity index of 3 points and a high prevalence of hypertension (57%), chronic kidney disease (28%) and obesity (27%). Baseline characteristics with the highest prognostic value for the primary endpoint by means of area under the receiver operating characteristic curve were male gender (0.63) and initial laboratory values including shock markers (lactate on ambient air 0.67; lactate with O2 supply 0.70), markers of inflammation (C-reactive protein 0.72, procalcitonin 0.80) and markers of compromised oxygenation (pO2 0.75 on ambient air), whereas age and comorbidities provided little prognostic information.

CONCLUSION

This analysis provides insights into the first consecutively hospitalised patients with confirmed COVID-19 at a Swiss tertiary care hospital during the initial period of the pandemic. Markers of disease progression such as inflammatory markers, markers for shock and impaired respiratory function provided the most prognostic information regarding severe COVID-19 progression in our sample.

References

  1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;92(4):401–2. doi:.https://doi.org/10.1002/jmv.25678
  2. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–6. doi:.https://doi.org/10.1016/j.ijid.2020.01.009
  3. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19)-Situation Report-97 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed 2020 June 16]
  4. Lemaitre JC, Perez-Saez J, Azman AS, Rinaldo A, Fellay J. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland. Swiss Med Wkly. 2020;150:w20295.
  5. Bernasconi L, Oberle M, Gisler V, Ottiger C, Fankhauser H, Schuetz P, et al. Diagnostic performance of a SARS-CoV-2 IgG/IgM lateral flow immunochromatography assay in symptomatic patients presenting to the emergency department. Clin Chem Lab Med. 2020;/j/cclm.ahead-of-print/cclm-2020-0635/cclm-2020-0635.xml.
  6. Roth JA, Ballouz T, Kouyos RD, Battegay M. Early off-label treatment during pandemics? A dilemma. Swiss Med Wkly. 2020;150:w20281.https://doi.org/10.4414/smw.2020.20281
  7. Vokinger KN, Nittas V, Witt CM, Fabrikant SI, von Wyl V. Digital health and the COVID-19 epidemic: an assessment framework for apps from an epidemiological and legal perspective. Swiss Med Wkly. 2020;150:w20282.
  8. Nittas V, von Wyl V. COVID-19 and telehealth: a window of opportunity and its challenges. Swiss Med Wkly. 2020;150:w20284. doi:.https://doi.org/10.4414/smw.2020.20284
  9. Scire J, Nadeau S, Vaughan T, Brupbacher G, Fuchs S, Sommer J, et al. Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft. Swiss Med Wkly. 2020;150:w20271.https://doi.org/10.4414/smw.2020.20271
  10. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. Swiss Med Wkly. 2020;150:w20203. doi:.https://doi.org/10.4414/smw.2020.20203
  11. World Health Organization. Clinical management of severe acute respiratory infection when novel conovirus (nCov) infection is suspected; interim guidance. Geneva: World Health Organization; Published 25 January 2020.
  12. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51. doi:.https://doi.org/10.1016/0895-4356(94)90129-5
  13. Juma S, Taabazuing MM, Montero-Odasso M. Clinical Frailty Scale in an Acute Medicine Unit: a Simple Tool That Predicts Length of Stay. Can Geriatr J. 2016;19(2):34–9. doi:.https://doi.org/10.5770/cgj.19.196
  14. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.; and the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052. doi:.https://doi.org/10.1001/jama.2020.6775
  15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi:.https://doi.org/10.1016/S0140-6736(20)30566-3
  16. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al.; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi:.https://doi.org/10.1001/jama.2020.5394
  17. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al.; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66. doi:.https://doi.org/10.1001/jama.2009.1297
  18. Suter-Widmer I, Christ-Crain M, Zimmerli W, Albrich W, Mueller B, Schuetz P ; ProHOSP Study Group. Predictors for length of hospital stay in patients with community-acquired pneumonia: results from a Swiss multicenter study. BMC Pulm Med. 2012;12(1):21. doi:.https://doi.org/10.1186/1471-2466-12-21

Most read articles by the same author(s)

<< < 1 2 3 4 > >>